Cargando…

A Systematic Review of the Efficacy and Safety Experience Reported for Sorafenib in Advanced Renal Cell Carcinoma (RCC) in the Post-Approval Setting

BACKGROUND: Sorafenib was FDA approved in 2005 for treatment of renal cell carcinoma (RCC) based on the results of the pivotal phase 3 clinical trial, TARGET (Treatment Approaches in Renal Cancer Global Evaluation Trial). Since that time, numerous clinical studies have been undertaken that substanti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fishman, Mayer N., Tomshine, Jin, Fulp, William J., Foreman, Pamela K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382117/ https://www.ncbi.nlm.nih.gov/pubmed/25830512 http://dx.doi.org/10.1371/journal.pone.0120877

Ejemplares similares

Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model
por: Yuen, J S P, et al.
Publicado: (2011)

Safety and clinical efficacy of everolimus in the treatment of advanced renal cell carcinoma (RCC)
por: Shahani, Rohan, et al.
Publicado: (2010)

Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib
por: Coppin, Chris
Publicado: (2010)

Efficacy and safety of sorafenib for advanced renal cell carcinoma: real-world data of patients with renal impairment
por: Tatsugami, Katsunori, et al.
Publicado: (2018)

Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma
por: Marta, Guilherme Nader, et al.
Publicado: (2021)

Urine Metabolomics for Renal Cell Carcinoma (RCC) Prediction: Tryptophan Metabolism as an Important Pathway in RCC
por: Liu, Xiaoyan, et al.
Publicado: (2019)

TOPK/PBK is phosphorylated by ERK2 at serine 32, promotes tumorigenesis and is involved in sorafenib resistance in RCC
por: Sun, Huimin, et al.
Publicado: (2022)

Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA
por: Izzedine, Hassane, et al.
Publicado: (2011)

Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma
por: Almhanna, Khaldoun, et al.
Publicado: (2009)

Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors
por: Kaymakcalan, M D, et al.
Publicado: (2013)

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
por: Rini, Brian I., et al.
Publicado: (2019)

Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies
por: Aragon-Ching, Jeanny B.
Publicado: (2021)

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis
por: FEDERICO, ALESSANDRO, et al.
Publicado: (2015)

The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study
por: Wada, Yoshiyuki, et al.
Publicado: (2017)

Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial)
por: Riaño, Ioana, et al.
Publicado: (2020)

Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma
por: Lee, Sangheun, et al.
Publicado: (2013)

Systemic therapy in metastatic renal cell carcinoma (mRCC): an evidence-based recommendation of the German interdisciplinary RCC guidelines group
por: Grünwald, V., et al.
Publicado: (2022)

Crossing Paths in Human Renal Cell Carcinoma (hRCC)
por: Gallego, Guadalupe Aparicio, et al.
Publicado: (2012)

Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)
por: Harrison, Michael R., et al.
Publicado: (2021)

A promising Prognostic risk model for advanced renal cell carcinoma (RCC) with immune-related genes
por: Cao, Peng, et al.
Publicado: (2022)

Retrospective analysis of sorafenib efficacy and safety in Chinese patients with high recurrence rate of post-hepatic carcinectomy
por: Wang, Desheng, et al.
Publicado: (2019)

Safety and efficacy of sorafenib in patients with advanced thyroid carcinoma: a phase II study (NCT02084732)
por: Fierro-Maya, Luis Felipe, et al.
Publicado: (2021)

Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence
por: Kang, Seong Hee, et al.
Publicado: (2018)

AB186. The efficacy and safety of sorafenib in Chinese patients with metastatic renal cell carcinoma and prognostic factors related to its efficacy
por: Yu, Xiaoteng, et al.
Publicado: (2015)

Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib
por: Flaig, T W, et al.
Publicado: (2010)

A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma
por: Wang, Hai-Tao, et al.
Publicado: (2019)

Comparative efficacy and safety of sunitinib vs sorafenib in renal cell carcinoma: A systematic review and meta-analysis
por: Liu, Xiu-Lan, et al.
Publicado: (2020)

Toxicity of Checkpoint Inhibition in Advanced RCC: A Systematic Review
por: Ornstein, Moshe C., et al.
Publicado: (2017)

Pivotal biomarker expression and drug screening in advanced ccRCC
por: Xiao, Wen, et al.
Publicado: (2020)

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
por: Choueiri, Toni K, et al.
Publicado: (2022)

Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC)
por: Bregni, Marco, et al.
Publicado: (2011)

Characteristics of Clear Cell Papillary Renal Cell Carcinoma (ccpRCC)
por: Rysz, Jacek, et al.
Publicado: (2021)

Defining candidate mRNA and protein EV biomarkers to discriminate ccRCC and pRCC from non-malignant renal cells in vitro
por: Zieren, Richard C., et al.
Publicado: (2021)

Co-Expression of Multiple PAX Genes in Renal Cell Carcinoma (RCC) and Correlation of High PAX Expression with Favorable Clinical Outcome in RCC Patients
por: Li, Lei, et al.
Publicado: (2023)

The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma
por: Qu, Xu-Dong, et al.
Publicado: (2012)

Therapeutic effect and adverse reaction of sorafenib in the treatment of advanced renal cancer
por: Qiu, Juhui, et al.
Publicado: (2019)

Cinryze(™) as the first approved C1 inhibitor in the USA for the treatment of hereditary angioedema: approval, efficacy and safety
por: Lunn, Michael, et al.
Publicado: (2010)

Efficacy and safety of sorafenib versus apatinib in the treatment of intermediate and advanced hepatocellular carcinoma: a comparative retrospective study
por: Wang, Yizhuo, et al.
Publicado: (2018)

Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis
por: Luo, Jia, et al.
Publicado: (2022)

Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval
por: Yamamoto, Yutaka, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_njtcbm6h2e49sn9bvitsf9fpk9